Biomea Fusion Stock Performance

BMEA Stock  USD 2.52  0.02  0.79%   
The firm shows a Beta (market volatility) of 2.18, which signifies a somewhat significant risk relative to the market. As the market goes up, the company is expected to outperform it. However, if the market returns are negative, Biomea Fusion will likely underperform. At this point, Biomea Fusion has a negative expected return of -0.63%. Please make sure to confirm Biomea Fusion's skewness, rate of daily change, and the relationship between the value at risk and accumulation distribution , to decide if Biomea Fusion performance from the past will be repeated at some point in the near future.

Risk-Adjusted Performance

Very Weak

 
Weak
 
Strong
Over the last 90 days Biomea Fusion has generated negative risk-adjusted returns adding no value to investors with long positions. Despite weak performance in the last few months, the Stock's technical and fundamental indicators remain somewhat strong which may send shares a bit higher in April 2025. The current disturbance may also be a sign of long term up-swing for the company investors. ...more

Actual Historical Performance (%)

One Day Return
0.4
Five Day Return
2.02
Year To Date Return
(31.44)
Ten Year Return
(85.12)
All Time Return
(85.12)
1
Heres Why Biomea Fusion, Inc. Is Among the Best Diabetes Stocks to Buy Under 10
01/06/2025
2
Biomea Fusion Reports New Preclinical Data on Icovamenib-Semaglutide Combination Study
01/07/2025
3
Biomea Fusion to Become a Diabetes Obesity Medicines Company
01/13/2025
4
Biomea Fusion stock hits 52-week low at 3.58 amid sharp decline - MSN
02/11/2025
5
Biomea Fusion to Unveil New Icovamenib Data at the 18th International Conference on Advanced Technologies Treatments for Diabetes
02/27/2025
6
Biomea Fusion, Inc. Reports Inducement Grant under Nasdaq Listing Rule 5635
03/03/2025
7
Acquisition by Thomas Butler of 305400 shares of Biomea Fusion at 9.8 subject to Rule 16b-3
03/05/2025
8
Disposition of 159120 shares by Erdtmann Rainer M of Biomea Fusion at 7.5023 subject to Rule 16b-3
03/12/2025
9
Disposition of 100000 shares by A2a Pharmaceuticals, Inc. of Biomea Fusion at 33.9931 subject to Rule 16b-3
03/17/2025
Begin Period Cash Flow112.2 M
Free Cash Flow-100 M
  

Biomea Fusion Relative Risk vs. Return Landscape

If you would invest  388.00  in Biomea Fusion on December 18, 2024 and sell it today you would lose (136.00) from holding Biomea Fusion or give up 35.05% of portfolio value over 90 days. Biomea Fusion is currently does not generate positive expected returns and assumes 4.3879% risk (volatility on return distribution) over the 90 days horizon. In different words, 39% of stocks are less volatile than Biomea, and 99% of all traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon.
  Expected Return   
       Risk  
Given the investment horizon of 90 days Biomea Fusion is expected to under-perform the market. In addition to that, the company is 5.14 times more volatile than its market benchmark. It trades about -0.14 of its total potential returns per unit of risk. The Dow Jones Industrial is currently generating roughly -0.02 per unit of volatility.

Biomea Fusion Market Risk Analysis

Today, many novice investors tend to focus exclusively on investment returns with little concern for Biomea Fusion's investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as Biomea Fusion, and traders can use it to determine the average amount a Biomea Fusion's price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.

Sharpe Ratio = -0.144

Best PortfolioBest Equity
Good Returns
Average Returns
Small Returns
CashSmall RiskAverage RiskHigh RiskHuge Risk
Negative ReturnsBMEA

Estimated Market Risk

 4.39
  actual daily
39
61% of assets are more volatile

Expected Return

 -0.63
  actual daily
0
Most of other assets have higher returns

Risk-Adjusted Return

 -0.14
  actual daily
0
Most of other assets perform better
Based on monthly moving average Biomea Fusion is not performing at its full potential. However, if added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Biomea Fusion by adding Biomea Fusion to a well-diversified portfolio.

Biomea Fusion Fundamentals Growth

Biomea Stock prices reflect investors' perceptions of the future prospects and financial health of Biomea Fusion, and Biomea Fusion fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Biomea Stock performance.

About Biomea Fusion Performance

By analyzing Biomea Fusion's fundamental ratios, stakeholders can gain valuable insights into Biomea Fusion's financial health, operational efficiency, and overall profitability, helping them make informed investment and management decisions. For instance, if Biomea Fusion has a high ROA and ROE, it suggests that the company is efficiently using its assets and equity to generate substantial profits, making it an attractive investment. Conversely, if Biomea Fusion has a low ROA and ROE, it may indicate underlying issues in asset and equity management, signaling a need for operational improvements.
Last ReportedProjected for Next Year
Return On Tangible Assets(0.53)(0.55)
Return On Capital Employed(0.82)(0.78)
Return On Assets(0.53)(0.55)
Return On Equity(0.80)(0.76)

Things to note about Biomea Fusion performance evaluation

Checking the ongoing alerts about Biomea Fusion for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Biomea Fusion help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.
Biomea Fusion generated a negative expected return over the last 90 days
Biomea Fusion has high historical volatility and very poor performance
Biomea Fusion has high likelihood to experience some financial distress in the next 2 years
Net Loss for the year was (117.25 M) with profit before overhead, payroll, taxes, and interest of 0.
Biomea Fusion currently holds about 149.63 M in cash with (96.59 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 5.11, which can makes it an attractive takeover target, given it will continue generating positive cash flow.
Biomea Fusion has a frail financial position based on the latest SEC disclosures
Roughly 64.0% of the company shares are held by institutions such as insurance companies
Latest headline from MacroaxisInsider: Disposition of 100000 shares by A2a Pharmaceuticals, Inc. of Biomea Fusion at 33.9931 subject to Rule 16b-3
Evaluating Biomea Fusion's performance can involve analyzing a variety of financial metrics and factors. Some of the key considerations to evaluate Biomea Fusion's stock performance include:
  • Analyzing Biomea Fusion's financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
  • Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Biomea Fusion's stock is overvalued or undervalued compared to its peers.
  • Examining Biomea Fusion's industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
  • Evaluating Biomea Fusion's management team can have a significant impact on its success or failure. Reviewing the track record and experience of Biomea Fusion's management team can help you assess the Company's leadership.
  • Pay attention to analyst opinions and ratings of Biomea Fusion's stock. These opinions can provide insight into Biomea Fusion's potential for growth and whether the stock is currently undervalued or overvalued.
It's essential to remember that evaluating Biomea Fusion's stock performance is not an exact science, and many factors can impact Biomea Fusion's stock market price. Therefore, it's also important to diversify your portfolio and not rely solely on one company or stock for your investments.

Complementary Tools for Biomea Stock analysis

When running Biomea Fusion's price analysis, check to measure Biomea Fusion's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Biomea Fusion is operating at the current time. Most of Biomea Fusion's value examination focuses on studying past and present price action to predict the probability of Biomea Fusion's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Biomea Fusion's price. Additionally, you may evaluate how the addition of Biomea Fusion to your portfolios can decrease your overall portfolio volatility.
Options Analysis
Analyze and evaluate options and option chains as a potential hedge for your portfolios
Aroon Oscillator
Analyze current equity momentum using Aroon Oscillator and other momentum ratios
Equity Search
Search for actively traded equities including funds and ETFs from over 30 global markets
Instant Ratings
Determine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance
Portfolio Backtesting
Avoid under-diversification and over-optimization by backtesting your portfolios
Share Portfolio
Track or share privately all of your investments from the convenience of any device